Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis

摘要: To cite this article: Jensen JM, Scherer A, Wanke C, Brautigam M, Bongiovanni S, Letzkus Staedtler F, Kehren J, Zuehlsdorf Schwarz T, Weichenthal Folster-Holst R, Proksch E. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy 2012; 67: 413–423. Abstract Background:  Topical corticosteroids calcineurin inhibitors are well-known treatments dermatitis (AD) but differ their efficacy side effects. We recently showed that valerate (BM) although clinically more efficient impaired barrier repair contrast to AD. Objective:  This study elucidates the mode action topical BM cream AD. Methods:  Lesional AD samples after treatment with either or were subjected gene profile analysis. Results:  Betamethasone resulted a significant reduction mRNA levels genes encoding markers immune cells inflammation, dendritic cells, T cytokines, chemokines, serine proteases, whereas exerted minor effects only. corroborates clinical finding reduces inflammation effectively than pimecrolimus. Genes molecules important for function affected. Both normalized filaggrin loricrin. BM, not pimecrolimus, significantly reduced rate-limiting enzymes lipid synthesis involucrin small proline-rich proteins, which covalently bind ceramides. may explain lack restoration functional stratum corneum layers observed treatment. Conclusion:  The profiles consistent our previous findings exert potent anti-inflammatory effect impair barrier. Corticosteroids still main severe acutely exacerbated AD; be preferable long-term stabilization.